Arginine depletion as a therapeutic approach for patients with COVID-19
The COVID-19 pandemic, caused by SARS-CoV-2, is a source of significant morbidity and mortality worldwide, and effective treatments are urgently needed. Clinical trials have largely focused on direct anti-viral therapies or on immunomodulation in patients with severe manifestations of COVID-19. One...
- Autores:
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2020
- Institución:
- Universidad de Bogotá Jorge Tadeo Lozano
- Repositorio:
- Expeditio: repositorio UTadeo
- Idioma:
- eng
- OAI Identifier:
- oai:expeditiorepositorio.utadeo.edu.co:20.500.12010/15606
- Acceso en línea:
- https://doi.org/10.1016/j.ijid.2020.10.100
http://hdl.handle.net/20.500.12010/15606
- Palabra clave:
- COVID-19
Pandemic
SARS-CoV-2
Clinical trials
Síndrome respiratorio agudo grave
COVID-19
SARS-CoV-2
Coronavirus
- Rights
- License
- Abierto (Texto Completo)
| Summary: | The COVID-19 pandemic, caused by SARS-CoV-2, is a source of significant morbidity and mortality worldwide, and effective treatments are urgently needed. Clinical trials have largely focused on direct anti-viral therapies or on immunomodulation in patients with severe manifestations of COVID-19. One therapeutic approach that remains to be clinically investigated is disruption of the host-virus relationship through amino acid restriction, a strategy utilized successfully in the setting of cancer treatment. Arginine is an amino acid that has been shown in non-clinical studies to be essential in the life cycle of many viruses. As such, arginine depletion may represent an effective therapeutic approach against SARS-CoV-2. Several argininemetabolizing enzymes in clinical development may represent a viable approach to induce a low arginine environment to treat COVID-19 and other viruses. Herein, we explore the rationale for arginine depletion as a therapeutic approach for COVID-19. |
|---|